MediGene Spins Out mTCR Programme - Independent Company Immunocore Limited Founded MediGene AG and three private investors have founded Immunocore Ltd, which will focus on the technology platform for monoclonal T-cell receptors (mTCR) of MediGene's UK subsidiary MediGene Ltd. MediGene holds a 38.5% stake in Immunocore Ltd and will be the largest shareholder of the new company.
[more...]